Lv1
100 积分 2025-10-24 加入
Novel antibody-drug conjugates based on DXd-ADC technology
2小时前
待确认
693P Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
1个月前
已完结
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
1个月前
已完结
Abstract 344: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models
1个月前
已关闭
皖公网安备34019202002308
